Clinical Trial

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2024 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open label phase 2 study for advanced sarcoma using metronomic doses of gemcitabine, doxorubicin and docetaxel, and nivolumab immunotherapy given intravenously.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04535713
Lead Sponsor Sarcoma Oncology Research Center, LLC
Conditions Sarcoma
Enrollment 260 participants
Start Date 2020-09-30
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-05